Vertex Pharmaceuticals Incorporated
- VRTX
- NASDAQ
- Biotechnology
- Cystic Fibrosis Drugs
- Biopharmaceuticals
$501.95
Today +0.44%Quote Oct 19, 2026, 08:00 PM UTC
−1.26%over the last month
Max drawdown −8.0%From 1-month high −4.9%3 months +4.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene.
Where the money comes from
Q2 2026 revenue $3.33B
- TRIKAFTA/KAFTRIO$2.50B74.9%
- ALYFTREK$573.6M17.2%
- Manufactured Product, Other$137.1M4.1%
- Other / not reported$126.0M3.8%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
6,400
Market value
$127.22B
Quote Oct 19
Floor
$500.01
0.4% below price
Resistance
$511.92
2.0% above price
Price vs analyst targets
56 analysts
Lowest target
$350.00Highest target
$665.00
$350.00Highest target
$665.00
- Price $501.95
- Average target $573.50
- Analysts' target range
Analysts' average target sits about 14% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about VRTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free